These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31374137)

  • 1. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?
    Malvi D; de Biase D; Fittipaldi S; Grillini M; Visani M; Pession A; D'Errico A; Vasuri F
    Histopathology; 2020 Jan; 76(2):265-274. PubMed ID: 31374137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
    Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
    Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
    Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
    Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
    Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
    Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
    Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
    Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
    Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
    Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
    Sasaki M; Sato Y; Nakanuma Y
    Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.
    Cirqueira CS; Felipe-Silva AS; Wakamatsu A; Marins LV; Rocha EC; de Mello ES; Alves VAF
    Pathol Oncol Res; 2019 Oct; 25(4):1363-1371. PubMed ID: 29464551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.
    Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M
    Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
    Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
    BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.
    Akiba J; Nakashima O; Hattori S; Naito Y; Kusano H; Kondo R; Nakayama M; Tanikawa K; Todoroki K; Umeno Y; Nakamura K; Sanada S; Yamaguchi R; Ogasawara S; Yano H
    J Clin Pathol; 2016 Oct; 69(10):846-51. PubMed ID: 26969740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
    Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
    Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.